rituximab biobetter (Fujian Haixi Pharmaceuticals)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Namerituximab biobetter (Fujian Haixi Pharmaceuticals)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Protein drugs > Recombinant protein

Mechanisms of ActionB-lymphocyte antigen CD20 inhibitors

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaPending

Originator CompaniesFujian Haixi Pharmaceuticals Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesFujian Haixi Pharmaceuticals Co Ltd

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A